The future potential treatment of high-risk, progressive, nmHSPC

One of the clinical questions that is now beginning to be asked really seriously is this one: “Just how aggressively should we treat a man with high-risk progressive prostate cancer after first-line therapy?” … READ MORE …

NICE recommends coverage of radium-223, but …

According to a recent report in Pharma Times, the National Institute for Health and Care Excellence (NICE) in the UK is recommending coverage of treatment with radium-223 dichoride (Xofigo) but has changed its mind about coverage of degarelix (Firmagon). … READ MORE …

Is treatment with degarelix really “better” than treatment with an LHRH agonist? Part II

Yesterday we commented (by request) on a paper by Klotz et al. suggesting that initial treatment with the LHRH antagonist degarelix might have benefits compared to initial treatment with an LHRH agonist such as leuprolide or goserelin acetate. … READ MORE …

Is treatment with degarelix really “better” than treatment with an LHRH agonist?

One of our regular readers has asked us to comment on a paper suggesting the possibility of “significant improvement” in various outcomes for men initially treated with the LHRH antagonist degarelix as compared to the LHRH agonists leuprolide acetate and goserelin acetate. … READ MORE …

NICE comments on proposed “new” use for degarelix

According to a media release issued by the National Institute for Clinical Excellence (NICE) in the UK, it has issued new draft guidance recommending treatment with degarelix (Firmagon) as an option for men with prostate cancer-related spinal metastases who are at risk for spinal cord compression. … READ MORE …

Adjuvant degarelix in combination with radiation therapy (instead of an LHRH agonist + an antiandrogen)

According to an announcement from the European Association for Urology (EAU) earlier today, data from a recently completed trial demonstrate that degarelix is “non-inferior” to the LHRH agonist goserelin acetate + the antiandrogen bicalutamide at reducing prostate volume in men with advanced hormone- dependent prostate cancer. … READ MORE …

Is an LHRH antagonist a better first-line hormone therapy than an LHRH agonist?

The question of whether an LHRH antagonist (such as degarelix) is really a better first-line hormone therapy than an LHRH agonist (e.g., leuprolide acetate) is still not fully answered. … READ MORE …